ArticleJournal of thoracic disease2026
Correlation between serum cerebral dopamine neurotrophic factor levels and severity of coronary artery lesions in acute myocardial infarction.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myocardial infarction (AMI) remains a leading cause of death and disability worldwide, and current biomarkers such as troponin, while sensitive, have limitations in early risk stratification and prognostic assessment. Cerebral dopamine neurotrophic factor (CDNF) is a neurotrophic protein that exerts cytoprotective effects under endoplasmic reticulum stress in preclinical models, but its role in human AMI has not been investigated. This study aimed to measure serum CDNF levels in patients with acute coronary syndrome (ACS), evaluate its diagnostic value for AMI, and assess its relationship with coronary lesion severity and short-term prognosis. Methods: A total of 141 ACS patients (72 AMI, 69 non-AMI) were enrolled. Serum CDNF was measured at admission, 24 h, and 96 h. Least absolute shrinkage and selection operator (LASSO)-logistic regression was used to build a diagnostic model. Prognostic endpoints were defined as hard Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) [cardiac death, recurrent myocardial infarction (MI), stroke, ischemia-driven revascularization] during 6-month follow-up. Results: Admission CDNF was higher in AMI [3.43±2.23 Conclusions: CDNF is elevated in AMI and correlates with infarct severity. It provides incremental diagnostic value beyond conventional markers. A dual role (damage marker
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.